Literature DB >> 20101210

Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.

J Lauring1, D P Cosgrove, S Fontana, J P Gustin, H Konishi, A M Abukhdeir, J P Garay, M Mohseni, G M Wang, M J Higgins, D Gorkin, M Reis, B Vogelstein, K Polyak, M Cowherd, P J Buckhaults, B H Park.   

Abstract

An oncogenic mutation (G49A:E17K) in the AKT1 gene has been described recently in human breast, colon, and ovarian cancers. The low frequency of this mutation and perhaps other selective pressures have prevented the isolation of human cancer cell lines that harbor this mutation thereby limiting functional analysis. Here, we create a physiologic in vitro model to study the effects of this mutation by using somatic cell gene targeting using the nontumorigenic human breast epithelial cell line, MCF10A. Surprisingly, knock in of E17K into the AKT1 gene had minimal phenotypic consequences and importantly, did not recapitulate the biochemical and growth characteristics seen with somatic cell knock in of PIK3CA hotspot mutations. These results suggest that mutations in critical genes within the PI3-kinase (PI3K) pathway are not functionally equivalent, and that other cooperative genetic events may be necessary to achieve oncogenic PI3K pathway activation in cancers that contain the AKT1 E17K mutation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101210      PMCID: PMC3042798          DOI: 10.1038/onc.2009.516

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.

Authors:  Steven J Isakoff; Jeffrey A Engelman; Hanna Y Irie; Ji Luo; Saskia M Brachmann; Rachel V Pearline; Lewis C Cantley; Joan S Brugge
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

2.  High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.

Authors:  Katsutoshi Oda; David Stokoe; Yuji Taketani; Frank McCormick
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

3.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

Authors:  Lao H Saal; Karolina Holm; Matthew Maurer; Lorenzo Memeo; Tao Su; Xiaomei Wang; Jennifer S Yu; Per-Olof Malmström; Mahesh Mansukhani; Jens Enoksson; Hanina Hibshoosh; Ake Borg; Ramon Parsons
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

4.  Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor.

Authors:  S Wennström; J Downward
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

5.  Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer.

Authors:  Dae-Sung Yoon; Robert P Wersto; Weibo Zhou; Francis J Chrest; Elizabeth S Garrett; Teag Kyu Kwon; Edward Gabrielson
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

6.  The PIK3CA gene is mutated with high frequency in human breast cancers.

Authors:  Kurtis E Bachman; Pedram Argani; Yardena Samuels; Natalie Silliman; Janine Ptak; Steve Szabo; Hiroyuki Konishi; Bedri Karakas; Brian G Blair; Clarence Lin; Brock A Peters; Victor E Velculescu; Ben Ho Park
Journal:  Cancer Biol Ther       Date:  2004-08-26       Impact factor: 4.742

7.  Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells.

Authors:  Abde M Abukhdeir; Brian G Blair; Keith Brenner; Bedri Karakas; Hiroyuki Konishi; Joselin Lim; Vanita Sahasranaman; Yi Huang; Judith Keen; Nancy Davidson; Michele I Vitolo; Kurtis E Bachman; Ben Ho Park
Journal:  Breast Cancer Res Treat       Date:  2006-03-16       Impact factor: 4.872

8.  AKT1(E17K) in human solid tumours.

Authors:  F E Bleeker; L Felicioni; F Buttitta; S Lamba; L Cardone; M Rodolfo; A Scarpa; S Leenstra; M Frattini; M Barbareschi; M Del Grammastro; M G Sciarrotta; C Zanon; A Marchetti; A Bardelli
Journal:  Oncogene       Date:  2008-05-26       Impact factor: 9.867

Review 9.  Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.

Authors:  P Workman
Journal:  Biochem Soc Trans       Date:  2004-04       Impact factor: 5.407

10.  Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner.

Authors:  Jayanta Debnath; Stephanie J Walker; Joan S Brugge
Journal:  J Cell Biol       Date:  2003-10-20       Impact factor: 10.539

View more
  29 in total

Review 1.  PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

2.  Basal but not luminal mammary epithelial cells require PI3K/mTOR signaling for Ras-driven overgrowth.

Authors:  Kristin A Plichta; Jessica L Mathers; Shelley A Gestl; Adam B Glick; Edward J Gunther
Journal:  Cancer Res       Date:  2012-09-24       Impact factor: 12.701

3.  Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung.

Authors:  Seung-Hyun Jung; Min Sung Kim; Sung-Hak Lee; Hyun-Chun Park; Hyun Joo Choi; Leeso Maeng; Ki Ouk Min; Jeana Kim; Tae In Park; Ok Ran Shin; Tae-Jung Kim; Haidong Xu; Kyo Young Lee; Tae-Min Kim; Sang Yong Song; Charles Lee; Yeun-Jun Chung; Sug Hyung Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

4.  Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones.

Authors:  Swathi Karthikeyan; Ian G Waters; Lauren Dennison; David Chu; Joshua Donaldson; Dong Ho Shin; D Marc Rosen; Paula I Gonzalez-Ericsson; Violeta Sanchez; Melinda E Sanders; Morgan V Pantone; Riley E Bergman; Brad A Davidson; Sarah C Reed; Daniel J Zabransky; Karen Cravero; Kelly Kyker-Snowman; Berry Button; Hong Yuen Wong; Paula J Hurley; Sarah Croessmann; Ben Ho Park
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

5.  PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.

Authors:  Michaela J Higgins; Julia A Beaver; Hong Yuen Wong; John P Gustin; Josh D Lauring; Joseph P Garay; Hiroyuki Konishi; Morassa Mohseni; Grace M Wang; Justin Cidado; Danijela Jelovac; David P Cosgrove; Akina Tamaki; Abde M Abukhdeir; Ben Ho Park
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

6.  PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

Authors:  Julia A Beaver; John P Gustin; Kyung H Yi; Anandita Rajpurohit; Matthew Thomas; Samuel F Gilbert; D Marc Rosen; Ben Ho Park; Josh Lauring
Journal:  Clin Cancer Res       Date:  2013-07-25       Impact factor: 12.531

Review 7.  The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.

Authors:  Josh Lauring; Ben Ho Park; Antonio C Wolff
Journal:  J Natl Compr Canc Netw       Date:  2013-06-01       Impact factor: 11.908

Review 8.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

9.  Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.

Authors:  Grace M Wang; Hong Yuen Wong; Hiroyuki Konishi; Brian G Blair; Abde M Abukhdeir; John P Gustin; D Marc Rosen; Samuel Ray Denmeade; Zeshaan Rasheed; William Matsui; Joseph P Garay; Morassa Mohseni; Michaela J Higgins; Justin Cidado; Danijela Jelovac; Sarah Croessmann; Rory L Cochran; Sivasundaram Karnan; Yuko Konishi; Akinobu Ota; Yoshitaka Hosokawa; Pedram Argani; Josh Lauring; Ben Ho Park
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

Review 10.  Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.

Authors:  Justin Cidado; Ben Ho Park
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-08-04       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.